Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.64 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.62 |
| ▸ | EHMT1 | Q9H9B1 | 7/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | KIF5B | P33176 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 7/20 | 0.59 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL900295 | 0.99 | AXL (0.62) | AXLEHMT2EHMT1RETKIF5B | |
| SCHEMBL13380202 | 0.88 | AXL (0.65) | AXLEHMT2EHMT1RETKIF5B | |
| SCHEMBL5097860 | 0.87 | EGFR (0.64) | AXLEHMT2EHMT1RETSRC | |
| SCHEMBL903068 | 0.87 | EGFR (0.64) | AXLEHMT2EHMT1RETSRC | |
| Hydrochloric Acid SCHEMBL6432089 | 0.86 | EGFR (0.62) | AXLEHMT2EHMT1RETSRC | |
| SCHEMBL15889700 | 0.85 | AXL (0.61) | AXLEHMT2EHMT1SRCKDR | |
| SCHEMBL14667305 | 0.85 | AXL (0.47) | AXLEHMT2EHMT1RETKIF5B | |
| SCHEMBL25281864 | 0.84 | SRC (0.66) | AXLRETKIF5BSRCKDR | |
| SCHEMBL5495221 | 0.84 | SRC (0.66) | AXLRETKIF5BSRCKDR | |
| SCHEMBL21573102 | 0.84 | AXL (0.61) | AXLEHMT2EHMT1SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768796-B1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2768796-B1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9365516-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365516-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2014-09-11 | — | — | US | disclosed |
| WO-2012044574-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012009723-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | EXELIXIS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-2350011-A1 | METHODS OF PREPARING QUINOLINE DERIVATIVES | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2339918-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GlaxoSmithKline LLC (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010056960-A1 | METHODS OF PREPARING QUINOLINE DERIVATIVES | EXELIXIS INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010036831-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GLAXOSMITHKLINE LLC (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036831-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GLAXOSMITHKLINE LLC (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | C5, C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AXL 4217/4885EHMT2 4785/4885EHMT1 4458/4885 |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | C5, C1S, C1R | AXL 4220/4885EHMT2 4790/4885EHMT1 4527/4885 |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | QDPR, CBR3, NQO2 | AXL 3026/4885EHMT2 3821/4885EHMT1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.